Efficacy and safety of a selective estrogen receptor β agonist, ERB‐041, in patients with rheumatoid arthritis: A 12‐week, randomized, placebo‐controlled, phase II study

@article{RomnBlas2010EfficacyAS,
  title={Efficacy and safety of a selective estrogen receptor $\beta$ agonist, ERB‐041, in patients with rheumatoid arthritis: A 12‐week, randomized, placebo‐controlled, phase II study},
  author={Jorge A. Rom{\'a}n-Blas and Santos Casta{\~n}eda and Maurizio Cutolo and Gabriel Herrero-Beaumont},
  journal={Arthritis Care \& Research},
  year={2010},
  volume={62}
}
Selective estrogen receptor β (ERβ) agonists have demonstrated relevant antiinflammatory effects in different animal models. This study aimed to compare the efficacy and safety of one of these agonists, ERB‐041, in subjects with rheumatoid arthritis (RA). 
AC-186, a selective nonsteroidal estrogen receptor β agonist, shows gender specific neuroprotection in a Parkinson's disease rat model.
TLDR
In male rats, 17β-estradiol, which activates ERβ and ERα with equal potency, did not show the same neuroprotective benefits as AC-186, so in addition to a beneficial safety profile for use in both males and females, a selective ERβ agonist has a differentiated pharmacological profile compared to 17 β-ESTradiol in males. Expand
Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential
TLDR
This review provides an overview and update of compounds that have been recently reported as modulators of ERs, with a particular focus on their potential clinical applications. Expand
Three Nuclear Receptors Involved in Gender-Related Proliferative Diseases (ER-β LXR-α, and LXR-β)
There are some diseases like autoimmune diseases, osteoporosis, and lymphangioleiomyomatosis where estrogen, the predominant female hormone, could play an important role. Despite major advances in med
The heart in rheumatoid arthritis: contrasting or misleading data from clinical research? Comment on the article by Giles et al.
TLDR
Though well-tolerated and safe, ERB-041 failed to demonstrate antiinflammatory efficacy in RA patients, despite evidence of strong activity in preclinical arthritis models, suggesting that selective ER agonism (both ER and ER ) would not have effects on regulation of inflammatory response in RA. Expand
The Effect of Antiestrogen Agents on Risk of Autoimmune Disorders in Patients with Breast Cancer
TLDR
Assessment of the incidence of systemic lupus erythematosus and rheumatoid arthritis following treatment with selective estrogen receptor modulators or aromatase inhibitors in women with breast cancer found that antiestrogen agents may have an important effect on risk of autoimmune disease. Expand
Selective estrogen receptor agonism lacks clinical benefit in rheumatoid arthritis: comment on the article by van Vollenhoven et al.
  • M. Cutolo
  • Medicine
  • Arthritis and rheumatism
  • 2010
TLDR
It is politely suggested that, based on the current evidence, there should not be any specific recommendations in regard to the best MRI protocol for obtaining images from which cartilage defects can be scored in population-based studies. Expand
Estrogens and interleukin-17 in arthritis and associated osteoporosis
Rheumatoid arthritis (RA), a disease characterized by persistent joint inflammation and joint destruction, is frequently associated with generalized osteoporosis. A female preponderance (3:1) isExpand
The Journal of Rheumatology Volume 42 , no . 1 Patients with Breast Cancer The Effect of Antiestrogen Agents on Risk of Autoimmune Disorders in
Objective. To investigate the relationship between antiestrogen therapy in women with breast cancer and risk of autoimmune disease. Methods.We used a national database to assess the incidence ofExpand
Effects of oestradiol and raloxifene on the induction and effector phases of experimental postmenopausal arthritis and secondary osteoporosis
TLDR
Treatment with oestradiol or raloxifene during the induction phase of CIA failed to affect arthritis and further experiments are needed to elucidate the exact mechanisms behind this finding. Expand
The role of testosterone and other hormonal factors in the development of rheumatoid arthritis
TLDR
These findings may improve the understanding of the RA disease process, and possibly also lead to new therapeutic strategies, including hormone substitution. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 22 REFERENCES
An estrogen receptor-beta agonist is active in models of inflammatory and chemical-induced pain.
TLDR
It is demonstrated that acutely administered ERB-041 is anti-hyperalgesic in preclinical models of chemical-induced and acute inflammatory pain, thus suggesting that ERb-041 may be useful for modulating pain associated with some types of inflammation. Expand
The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine.
TLDR
The observed lack of clinical benefit in RA patients treated with an ERalpha agonist, in association with a clear biologic response to the study drug, provides evidence that a biologically relevant ERalpha-mediated estrogenic effect is not associated with a clinically relevant effect on RA symptoms and signs. Expand
Evaluation of an Estrogen Receptor-β Agonist in Animal Models of Human Disease
TLDR
It is concluded that ERβ does not mediate the bone-sparing activity of estrogen on the rat skeleton and that it does not affect ovulation or ovariectomy-induced weight gain. Expand
Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials.
TLDR
There were no statistically significant differences in the risk of developing RA or the severity of RA between the PHT and placebo groups. Expand
Estrogen Receptor-β: Recent Lessons from in Vivo Studies
TLDR
A clear role for ERβ has been established in the ovary, cardiovascular system, and brain as well as in several animal models of inflammation including arthritis, endometriosis, inflammatory bowel disease, and sepsis. Expand
Amelioration of collagen-induced arthritis and immune-associated bone loss through signaling via estrogen receptor alpha, and not estrogen receptor beta or G protein-coupled receptor 30.
TLDR
In a well-established model of postmenopausal RA, ERalpha, but not ERbeta or GPR-30 signaling, was shown to ameliorate the disease and the associated development of osteoporosis. Expand
Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis.
TLDR
Two years of HRT in women with active RA had significant ameliorating effects on inflammation, DAS28 response, and BMD and was associated with slower progression of radiological joint destruction and is suggested to be used in addition to conventional therapy in the management of postmenopausal patients with RA. Expand
Osteoarthritis associated with estrogen deficiency
TLDR
A better understanding of how estrogen acts on joints and other tissues in OA will aid the development of specific and safe estrogen ligands as novel therapeutic agents targeting the OA joint as a whole organ. Expand
Drug and Cell Type-Specific Regulation of Genes with Different Classes of Estrogen Receptor β-Selective Agonists
TLDR
Estrogens produce biological effects by interacting with two estrogen receptors, ERα and ERβ, and while most of the genes were commonly regulated by ERβ-selective agonists and E2, there were some genes regulated that were distinct from each other and E1, suggesting that different ER β-selectives might produce distinct biological and clinical effects. Expand
Sex steroid receptors in rheumatoid arthritis.
TLDR
The results indicate that sex steroid receptors are present in RA and non-inflamed synovial tissues, including inflammatory cells in RA, and suggest that sex steroids may play important roles in the regulation of inflammation of RAsynovial tissue. Expand
...
1
2
3
...